Lars N.
- Country
- Sweden
- Department
- Oncology and Hematology
Research Overview
- A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
- Phase II Multicenter Study on Azacitidine Efficacy and Safety in VEXAS Syndrome Patients
- Phase II Multicenter Study on Azacitidine for Minimal Residual Disease Management Post-Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome
Data & Insights
Has run more than one trial at 40 of 138 partner sites.
Specializations
Hematologic Disorders
The investigator specializes in treating myelodysplastic syndromes (MDS), with particular emphasis on managing various risk categories from very low to intermediate risk cases.
- Risk-stratified MDS treatment approaches
- IPSS-R classification implementation
- Novel therapeutic strategies
Their work encompasses comprehensive evaluation of treatment outcomes in different MDS risk categories.
Anemia Management
Focuses on innovative approaches to treating transfusion-dependent anemia in MDS patients, exploring both established and experimental therapeutic options.
- Red blood cell transfusion independence
- Erythropoiesis-stimulating agents
- Hemoglobin optimization strategies
The investigator evaluates various treatment modalities to reduce transfusion dependency in MDS patients.
Disease Monitoring
Specializes in minimal residual disease (MRD) monitoring and prevention of clinical events in hematologic conditions.
- Long-term safety monitoring
- Disease progression assessment
- Relapse prevention strategies
Their research includes evaluation of treatment safety profiles and long-term patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.